D. E. Shaw & Co. Inc. Has $8.47 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

D. E. Shaw & Co. Inc. boosted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 220.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 442,070 shares of the company's stock after purchasing an additional 304,003 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.56% of Viridian Therapeutics worth $8,474,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG raised its position in shares of Viridian Therapeutics by 6.1% during the 4th quarter. Deutsche Bank AG now owns 402,874 shares of the company's stock valued at $7,723,000 after acquiring an additional 23,327 shares in the last quarter. Deep Track Capital LP grew its position in shares of Viridian Therapeutics by 20.6% during the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares during the last quarter. Concentric Capital Strategies LP acquired a new stake in Viridian Therapeutics during the fourth quarter worth about $1,697,000. Crestline Management LP lifted its holdings in Viridian Therapeutics by 31.7% in the fourth quarter. Crestline Management LP now owns 200,857 shares of the company's stock worth $3,850,000 after acquiring an additional 48,315 shares during the last quarter. Finally, Cutter Capital Management LP boosted its stake in Viridian Therapeutics by 21.2% in the fourth quarter. Cutter Capital Management LP now owns 628,677 shares of the company's stock valued at $12,052,000 after acquiring an additional 110,000 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on VRDN shares. Needham & Company LLC lowered their price objective on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JMP Securities decreased their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada cut their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN traded down $0.12 on Monday, reaching $12.82. The company's stock had a trading volume of 471,519 shares, compared to its average volume of 1,192,931. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm's 50 day moving average is $13.41 and its two-hundred day moving average is $17.10. The stock has a market cap of $1.05 billion, a PE ratio of -2.97 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.